Alector Stock

Alector Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Alector (ALEC) as of Aug 22, 2026 is 128.76 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 193.12 % — a change of -33.33% (lower).

Cash Conversion

128.76 %

YoY

-33.33%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Alector is 2026 128.76 % . Cash Conversion Rate (OCF/Net Income) of Alector was 2025 193.12 % . It decreases by -33.33% lower compared to the previous year.

The Alector Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-243.96 USD
Jan 1, 2019
99.50 USD
Jan 1, 2020
91.13 USD
Jan 1, 2021
-1,065.72 USD
Jan 1, 2022
15.25 USD
Jan 1, 2023
141.24 USD
Jan 1, 2024
193.12 USD
Jan 1, 2025
128.76 USD
The Alector Cash Conversion history
YEARCash ConversionYoY
128.76 %-33.33%
193.12 %+36.73%
141.24 %+826.19%
15.25 %-101.43%
-1,065.72 %-1,269.45%
91.13 %-8.41%
99.50 %-140.78%
-243.96 %-545.88%
54.71 %-36.37%
85.99 %
Access this data via the Eulerpool API

Alector Stock analysis

What does Alector do? Alector Inc. is a biotechnology company that was founded in 2013. The company's core competency is developing targeted therapies for previously incurable neurodegenerative diseases. The company is based in South San Francisco, California, and was founded by a group of renowned scientists. The founders aimed to develop innovative approaches to treat Alzheimer's and other neurodegenerative diseases by drawing inspiration from the processes of the immune system. Alector has a unique business model based on identifying antibodies to combat neurodegeneration. The company works closely with academics, pharmaceutical partners, and clinicians to develop drug candidates targeting various aspects of these serious diseases. Alector has developed a platform technology called the "Lead-Selective Integrated Discovery Platform" (LSP) that sets it apart. This platform is capable of identifying specific antibodies that can help inhibit disease mechanisms in neurodegenerative diseases. Alector has several products in various stages of development. A promising drug, AL001, is currently in Phase 1b/2a of clinical development for the treatment of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). The drug aims to prevent overactivation of the immune system in the brain, which can contribute to disease symptoms. The company is also working on another drug, AL002, targeting Alzheimer's disease. It is still in preclinical development. Alector has also entered into a partnership with AbbVie Inc. (NYSE: ABBV) to develop antibody-based therapies for Alzheimer's disease and other neurological disorders. In addition to developing drug candidates, Alector also collaborates with other companies to make its technology platform accessible to other industries. In 2019, the company signed an agreement with GlaxoSmithKline plc (NYSE: GSK) granting GlaxoSmithKline access to the LSP platform. In summary, Alector Inc. is a leading biotechnology company specializing in the development of antibody-based therapies for neurodegenerative diseases. With innovative technology platforms and partnerships with other companies, Alector aims to create new treatment options for incurable diseases such as Alzheimer's and ALS. Alector is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alector stock

Cash Conversion Rate (OCF/Net Income) of Alector is 128.76 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Alector changed from 193.12 % to 128.76 %, representing a -33.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Alector since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Alector with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Alector

All Key Metrics — Alector